Low dose Pfizer-Lilly painkiller fails late stage study

A lower dose of non-opioid painkiller, tanezumab, developed by Pfizer and Eli Lilly failed to meet main goals in a late-stage study in patients with moderate-to-severe osteoarthritis.
Source: PharmaManufacturing.com - Category: Pharmaceuticals Source Type: news